Abstract 404MO
Background
Tertiary lymphoid structures (TLS) are organized aggregates of immune cells that form postnatally in non-lymphoid tissues and arise under pathological conditions. The prognostic and predictive value of TLS in the tumor microenvironment (TME) has strengthened interest as potential mediators of antitumor immunity.
Methods
Immunohistochemistry and multispectral fluorescent were used to evaluate the TLS heterogeneity along with TME cell-infiltrating characterizations. We comprehensively assessed the prognostic and immunological implications of the TLS heterogeneity in 625 patients with ccRCC from multiply cohorts. Associations between TLS heterogeneity and immunologic activities were assessed by the quantification of immune cells infiltration.
Results
TLS typically comprises B-cell follicles with germinal centers and are surrounded by T-cell zones and dendritic cells. TLS infiltrates were identified in 34.2% of the ccRCC samples, with intratumoral, peritumoral, and both in 37.8%, 74.1%, and 11.9% of the TLS-positive cases, respectively. A higher proportion of early TLS was found in peritumoral TLS (P=0.016), while intratumoral TLS mainly comprised secondary follicle-like (P=0.004). Kaplan-Meier analyses indicated that the presence of mature TLS (namely SFL-TLS, with CD23+ germinal center) markedly correlated with both better survival. Notably, presence of TLS, especially intratumoral TLS and SFL-TLS significantly correlated with better survival and objective reflection rate for ccRCC patients receiving anti-PD-1/PD-L1 immunotherapies. Interestingly, in ccRCC samples with the presence of peritumoral TLS enriched with primary follicle-like TLS, the proportion of tumor-associated macrophages and Treg infiltration in the peritumoral regions increased prominently, showing a typical suppressive TME characterizations.
Conclusions
In conclusion, this study for the first time revealed the implications of TLS localization and maturation heterogeneity on the immunological status and responses of ccRCC, allowing the identification of immunophenotypes and the improvement of immunotherapeutic effectiveness for ccRCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Shanghai Municipal Health Bureau (No.2020CXJQ03).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
402O - A randomized phase III trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary
Presenter: Xin Liu
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
Invited Discussant 402O
Presenter: Linda Mileshkin
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Webcast
405MO - Pan-cancer analysis of 4-1BB transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors
Presenter: Yuji Uehara
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
Invited Discussant 404MO and 405MO
Presenter: Aaron Hansen
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Webcast
74MO - Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
Presenter: Do-Youn Oh
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
75MO - Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3+ tumors: Focus on Asian pts
Presenter: Yasutoshi Kuboki
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
76MO - Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas
Presenter: Tom Wei-Wu Chen
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
77MO - A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors
Presenter: Rujiao Liu
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast